【#圣湘生物回应核聚变相关投资#：系公司实控人个人投资[话筒]】有投资者在互动平台提问圣湘生 物：最近看到一些媒体报道了公司实控人投资了可控核聚变企业上海鸿鹄聚变，请问属实吗？圣湘生物 回应称，鸿鹄聚变（上海）能源科技有限公司成立于2023年，系圣湘生物实控人、董事长戴立忠投资创 立的企业，也是国内首家专注于高温超导仿星器路线的商业聚变企业。与托卡马克技术路线相比，仿星 器通过精密设计的三维高温超导线圈电流产生磁场，无需依赖等离子体电流，更契合于稳态运行的商用 聚变反应堆。目前，鸿鹄聚变具备世界领先的仿星器设计开发能力。戴立忠不参与鸿鹄聚变的日常运营 工作，旨在为这个领域的世界级科学家与工程师创新创业搭平台、引资源、打基础。目前该项目只涉及 戴立忠的个人投资，上市公司是否参与投资，需结合实际发展需要及战略规划等情况审慎决定。（人民 财讯） ...

Core Viewpoint - The article discusses the investment of Shengxiang Biological's actual controller and chairman, Dai Lizhong, in a controlled nuclear fusion company, Shanghai Honghu Fusion, which is the first domestic enterprise focusing on high-temperature superconducting stellarator technology [1] Company Summary - Shengxiang Biological confirmed that Shanghai Honghu Fusion was established in 2023 and is founded by Dai Lizhong, who is also the actual controller of Shengxiang Biological [1] - Honghu Fusion is recognized as a leading company in the design and development of stellarator technology, which utilizes precisely designed three-dimensional high-temperature superconducting coils to generate magnetic fields without relying on plasma current [1] - Dai Lizhong does not participate in the daily operations of Honghu Fusion, aiming to provide a platform for world-class scientists and engineers in the field [1] Investment Context - The investment by Dai Lizhong is personal and does not currently involve Shengxiang Biological, with any potential investment by the listed company to be decided based on actual development needs and strategic planning [1]

Core Viewpoint - The establishment of Honghu Fusion (Shanghai) Energy Technology Co., Ltd. marks a significant step in China's pursuit of commercial fusion energy, with a focus on high-temperature superconducting stellarator technology, which is seen as a strategic high ground in global energy technology competition [1] Company Summary - Saint Shine (688289.SH) has indicated its interest in the fusion energy sector, which is recognized as a potential solution to global energy crises and environmental issues [1] - The company’s actual controller and chairman, Dai Lizhong, founded Honghu Fusion in 2023, making it the first domestic enterprise focused on commercial fusion using stellarator technology [1] - Honghu Fusion possesses world-leading capabilities in stellarator design and development [1] Industry Summary - Shanghai has identified nuclear fusion as a key future industry, emphasizing its importance in the global energy landscape [1] - The collaboration between Honghu Fusion and Shanghai Jiao Tong University aims to enhance domestic commercial fusion development through joint laboratory construction, technology research, and talent cultivation [1] - The project is currently funded solely by Dai Lizhong's personal investment, with any potential involvement from the listed company subject to careful consideration and necessary approvals [1]

Core Viewpoint - The chairman of Shengxiang Bio, Dai Lizhong, has established a personal investment in a fusion energy company named Honghu Fusion, which does not involve the company's operational activities [1] Group 1 - Dai Lizhong is identified as both an investor and the actual controller of Honghu Fusion (Shanghai) Energy Technology Co., Ltd [1] - The project is solely a personal investment by Dai Lizhong, with no current involvement from Shengxiang Bio in the operations of Honghu Fusion [1] - Shengxiang Bio emphasizes that any potential investment by the listed company will depend on actual development needs and strategic planning, requiring board and shareholder approval [1]

Core Viewpoint - The company has received a medical device registration certificate for its nucleic acid test kits for human coronaviruses, influenza viruses, and novel coronaviruses, which are essential for accurate diagnosis and treatment of respiratory infections [1][2]. Product Registration Details - The newly certified test kits utilize multiplex fluorescent PCR technology, offering high sensitivity, specificity, and ease of use, capable of accurately identifying three pathogens in as little as 30 minutes [2]. - The product line integrates with the company's existing rapid detection solutions for respiratory infections, allowing for unified sampling and amplification, thus enabling simultaneous detection of various common respiratory pathogens [2]. Impact on the Company - The test kits address the clinical challenges posed by respiratory pathogens, which often present similar symptoms, making accurate diagnosis difficult. The need for efficient and precise testing methods is critical for clinical decision-making [1][2]. - The company aims to enhance its product offerings in respiratory infection diagnostics, contributing to improved treatment levels for infectious diseases and supporting public health efforts against antimicrobial resistance [2].

公司本次获证的人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒采用多 重荧光 PCR 技术，具备高灵敏度、高特异性、操作简便等优势，最快可在 30 分钟内 完成 3 种病原的精准鉴别。该产品可结合公司现有的呼吸道感染核酸快速检测方案， 统一采样、统一扩增，实现多种常见呼吸道病原体同步检测。该系列产品已覆盖常见 呼吸道病毒、细菌、真菌、非典型病原体及耐药基因，广泛适用于门诊、急诊及住院 等多种场景，同时支持基于患者临床表现、地域及季节流行特征，灵活组合不同检测 产品，更好应对多病原共流行和混合感染等复杂局面，为临床精准用药和抗菌药物管 理提供有力支撑。 证券代码：688289 证券简称：圣湘生物 公告编号：2025-064 圣湘生物科技股份有限公司 关于自愿披露相关产品取得医疗器械注册证 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）的产品人冠状病毒、 副流感病毒、新型冠状病毒核酸检测试剂盒（荧光 PCR 法）于近日收到由国家药品 监督管理局颁发的《医疗器 ...

南财智讯9月30日电，圣湘生物公告，公司收到国家药品监督管理局颁发的《医疗器械注册证》，产品 名称为人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒（荧光PCR法）。该产品用于体外定性 检测具有新型冠状病毒感染或其他呼吸道感染相关症状人群的咽拭子样本中的人冠状病毒、副流感病毒 和新型冠状病毒的核酸。产品的获批有助于提升感染性疾病诊疗水平，为临床精准用药和抗菌药物管理 提供有力支撑。但产品未来的市场表现存在不确定性。 ...

Core Viewpoint - Shengxiang Bio (688289.SH) has received a medical device registration certificate from the National Medical Products Administration for its nucleic acid test kits for human coronavirus, parainfluenza virus, and novel coronavirus, utilizing multiplex fluorescent PCR technology [1] Group 1: Product Features - The nucleic acid test kits demonstrate high sensitivity, high specificity, and ease of operation, capable of accurately identifying three pathogens in as little as 30 minutes [1] - The product can be integrated with the company's existing rapid detection solutions for respiratory infections, allowing for unified sampling and amplification to detect multiple common respiratory pathogens simultaneously [1] Group 2: Application and Market Scope - This series of products covers common respiratory viruses, bacteria, fungi, atypical pathogens, and drug resistance genes, making it suitable for outpatient, emergency, and inpatient settings [1] - The kits support flexible combinations of different testing products based on patient clinical presentations, regional characteristics, and seasonal prevalence, effectively addressing complex situations of co-circulation and mixed infections, thereby providing strong support for precise medication and antibiotic management in clinical settings [1]

智通财经APP讯，圣湘生物(688289.SH)发布公告，公司的产品人冠状病毒、副流感病毒、新型冠状病 毒核酸检测试剂盒(荧光PCR法)于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。 公司本次获证的人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒采用多重荧光PCR技术，具备 高灵敏度、高特异性、操作简便等优势，最快可在30分钟内完成3种病原的精准鉴别。该产品可结合公 司现有的呼吸道感染核酸快速检测方案，统一采样、统一扩增，实现多种常见呼吸道病原体同步检测。 该系列产品已覆盖常见呼吸道病毒、细菌、真菌、非典型病原体及耐药基因，广泛适用于门诊、急诊及 住院等多种场景，同时支持基于患者临床表现、地域及季节流行特征，灵活组合不同检测产品，更好应 对多病原共流行和混合感染等复杂局面，为临床精准用药和抗菌药物管理提供有力支撑。 ...

Core Viewpoint - The implementation of equity incentives has significantly boosted the performance of many companies in the A-share market, with an average increase of over 64% in the equity incentive sector, outperforming major indices like the Shanghai Composite Index and the ChiNext Index [1][2]. Group 1: Performance of Companies - The equity incentive sector has seen 27 stocks more than double in value this year, with New Yisheng leading at a 354.85% increase [1]. - Companies like Nanya New Materials and Zhongji Xuchuang have also shown impressive growth, with revenue increases of over 43% and net profit increases of nearly 58% [1]. - The majority of companies that implemented equity incentives have experienced significant performance improvements, with 88% reporting revenue growth and 76.88% reporting net profit growth [2]. Group 2: Impact of Equity Incentives - Equity incentives align the interests of employees with those of the company, enhancing motivation and innovation, which in turn drives company performance in various areas [2]. - The market perceives companies that implement equity incentives as more confident in their future growth, leading to higher stock valuations [2]. Group 3: Future Growth Potential - Recent data indicates that 63 stocks have implemented equity incentives since September, with many expected to achieve high growth rates in net profit, exceeding 15% in the coming years [3]. - Shaoneng Co., with a low price-to-book ratio of 1.32, is highlighted as a company with significant growth potential in the clean energy sector [3]. - The company has set ambitious performance targets for its equity incentive plan, aiming for a net profit growth rate of at least 30% in 2025 and 97% by 2027 [4][5]. Group 4: Market Trends - The slow bull market in A-shares is creating favorable conditions for investment in the equity incentive sector, with expectations of more quality companies emerging [6]. - The increasing recognition of the importance of equity incentives among companies is likely to lead to more opportunities for investors [6].